about
Arc/Arg3.1 regulates an endosomal pathway essential for activity-dependent β-amyloid generationTwo N-terminal domains of Kv4 K(+) channels regulate binding to and modulation by KChIP1The antibody aducanumab reduces Aβ plaques in Alzheimer’s diseasePhosphorylation of the AMPA receptor subunit GluR2 differentially regulates its interaction with PDZ domain-containing proteinsNeuronal development is promoted by weakened intrinsic antioxidant defences due to epigenetic repression of Nrf2Stereochemistry-activity relationship of orally active tetralin S1P agonist prodrugs.Heat shock protein 90: inhibitors in clinical trials.Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway.Dimethyl fumarate and monoethyl fumarate exhibit differential effects on KEAP1, NRF2 activation, and glutathione depletion in vitro.Fumarates modulate microglia activation through a novel HCAR2 signaling pathway and rescue synaptic dysregulation in inflamed CNS.Repurposing the NRF2 Activator Dimethyl Fumarate as Therapy Against Synucleinopathy in Parkinson's DiseaseBG-12 (dimethyl fumarate): a review of mechanism of action, efficacy, and safety.Tolerability and pharmacokinetics of delayed-release dimethyl fumarate administered with and without aspirin in healthy volunteers.Pharmacodynamics of Dimethyl Fumarate Are Tissue Specific and Involve NRF2-Dependent and -Independent Mechanisms.Discovery of a highly selective chemical inhibitor of matrix metalloproteinase-9 (MMP-9) that allosterically inhibits zymogen activation.Synapto-depressive effects of amyloid beta require PICK1DMF, but not other fumarates, inhibits NF-κB activity in vitro in an Nrf2-independent manner.The NRF2 transcriptional target, OSGIN1, contributes to monomethyl fumarate-mediated cytoprotection in human astrocytes.Dimethyl fumarate alters microglia phenotype and protects neurons against proinflammatory toxic microenvironments.Discovery of BIIB042, a Potent, Selective, and Orally Bioavailable γ-Secretase Modulator.Dimethyl fumarate improves white matter function following severe hypoperfusion: Involvement of microglia/macrophages and inflammatory mediators.Extension of the thrombolytic time window with minocycline in experimental stroke.Discovery of 4-aminomethylphenylacetic acids as γ-secretase modulators via a scaffold design approach.Methylene amine substituted arylindenopyrimidines as potent adenosine A(2A)/A(1) antagonists.Optimization of arylindenopyrimidines as potent adenosine A(2A)/A(1) antagonists.Activation of silent synapses by rapid activity-dependent synaptic recruitment of AMPA receptors.BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90.Substituted thieno[2,3-d]pyrimidines as adenosine A2A receptor antagonists.BIIB042, a novel γ-secretase modulator, reduces amyloidogenic Aβ isoforms in primates and rodents and plaque pathology in a mouse model of Alzheimer's disease.Induction of matrix metalloproteinase, cytokines and chemokines in rat cortical astrocytes exposed to plasminogen activators.1-Hydroxy-2-pyridinone-based MMP inhibitors: synthesis and biological evaluation for the treatment of ischemic stroke.Potent PDZ-Domain PICK1 Inhibitors that Modulate Amyloid Beta-Mediated Synaptic DysfunctionAddendum: The antibody aducanumab reduces Aβ plaques in Alzheimer’s diseaseFumarates Promote Cytoprotection of Central Nervous System Cells against Oxidative Stress via the Nuclear Factor (Erythroid-Derived 2)-Like 2 Pathwaybeta-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: part 2. Optimization of alpha-amino substituentsSynthesis and SAR of alpha-sulfonylcarboxylic acids as potent matrix metalloproteinase inhibitorsDesign and characterization of optimized adenosine A₂A/A₁ receptor antagonists for the treatment of Parkinson's diseaseDiscovery of novel Cobactin-T based matrix metalloproteinase inhibitors via a ring closing metathesis strategyNeuroprotective dimethyl fumarate synergizes with immunomodulatory interferon beta to provide enhanced axon protection in autoimmune neuroinflammationTherapeutic strategies for targeting neurodegenerative protein misfolding disorders
P50
Q24294891-4EF03077-A09D-4773-BA99-E842A8EBC64CQ27643180-CFED0391-4B2D-4C5B-ADDC-0A9FA0CCCABEQ28005463-2D83A0A9-4325-43E4-9E49-DE2FFED20F06Q28139757-147D9CBD-C764-4371-B19D-CC6071D57D68Q28394694-E81D3C49-52F8-49E7-B100-C1BE6A87F970Q30432808-57019B98-0F45-4A82-8EFC-9E3C0380CF5DQ34091401-38F299D7-83D0-4A62-9E0A-FAEF1AD48916Q34627230-29E29766-F597-41E7-B867-81B61B3A6602Q35582048-085083AE-7291-436D-8D35-5262825A691AQ35856171-39F184F1-54D3-43F6-90AB-57522C707899Q37091371-4EAAF2E2-A401-498B-AD38-29A43B56D029Q38153082-B1850377-1674-4544-82F8-7B631650B0CFQ38442717-39B63F56-6456-4645-8624-F8B5D3F5B504Q38449822-B482BCFE-B4F4-4576-9900-A70657006B2FQ38634770-C0EB8579-5DBB-4A8D-AF79-E0DAC2A067ACQ38708789-076C1F50-67DB-4BD3-9F1C-0AB78E60CDE6Q38871531-740BBCBA-68D1-41D0-A6B7-E51FB65D146CQ38970297-3D074991-FC08-474E-80AC-E5FA376FC4FCQ39304653-E6C250E1-15F9-4798-8257-5B677008A92AQ39511082-145E7162-0ABD-47AB-A0C9-26CAA431F32AQ40163126-E8FC836C-1ED4-433D-9878-E61565A9047EQ41812595-F6A85F7F-FB02-47DE-8E85-99330DE63736Q42725158-576CD7FB-1160-4EFA-9FA7-617909275404Q43116729-B1F5B20B-89E5-46AE-A9CC-76DF977A96D3Q43118400-98820465-3D2F-43AA-9900-C063BD49232DQ43697226-C9BBE84D-AE2D-42D5-8EC6-C781D888049EQ46047999-A5A54F52-2936-4CB4-BEFC-B13ED085C7C1Q46208935-7E3EA697-E803-4852-92B2-81CFFCCE2C9DQ46621035-D75E6B5D-61A7-4E98-8116-33FD1C168B93Q48228189-A988CA8B-8F06-4496-BA62-BC7DC4C78790Q53127030-57122644-54A7-4385-8041-5EEC754A5079Q58759665-39C95C58-1C94-411A-A071-714DC858520EQ59082751-53A8D95E-C114-4E7F-A684-BB0F41C55919Q59344888-2F66EFC9-1377-47E5-B4F1-79F2B72AB74EQ80208049-F4AD0455-2EEE-4CD7-92F0-8868AB51217AQ83189085-414D3CF4-156E-43DC-A275-6A8EEB145EB3Q83218869-D4514D53-0BE2-442B-BC6C-BC076F81257EQ84957679-08AA98B8-5761-4C65-A492-A539A3BB240BQ87680428-2A60E469-01DD-43A8-A76E-52D318D66E4FQ89104866-F96E1225-0C49-435D-8E3C-7940B184985D
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Robert Scannevin
@ast
Robert Scannevin
@en
Robert Scannevin
@es
Robert Scannevin
@nl
Robert Scannevin
@sl
type
label
Robert Scannevin
@ast
Robert Scannevin
@en
Robert Scannevin
@es
Robert Scannevin
@nl
Robert Scannevin
@sl
prefLabel
Robert Scannevin
@ast
Robert Scannevin
@en
Robert Scannevin
@es
Robert Scannevin
@nl
Robert Scannevin
@sl
P106
P21
P31
P496
0000-0002-5749-2785